Adverse event profile of tigecycline: Data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 6, 2012, Pages 967-970

  Kadoyama, Kaori ^a   Sakaeda, Toshiyuki ^a   Tamon, Akiko ^b   Okuno, Yasushi ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b Kyoto Constella Technologies Co Ltd   (Japan)

Author keywords

Adverse event; Data mining; Pharmacovigilance; Tigecycline

Indexed keywords

TIGACYL; TIGECYCLINE; UNCLASSIFIED DRUG;

ACINETOBACTER INFECTION; ACUTE KIDNEY FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ARTIFICIAL NEURAL NETWORK; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTEREMIA; BACTERIAL INFECTION; BAYES THEOREM; BILIRUBIN BLOOD LEVEL; CHILL; CHOLESTASIS; DATA MINING; DISEASE ASSOCIATION; DRUG FATALITY; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; KIDNEY FAILURE; LIVER FAILURE; MULTIPLE ORGAN FAILURE; NAUSEA; OFF LABEL DRUG USE; PANCREATITIS; PRESCRIPTION; QUANTITATIVE ANALYSIS; RESPIRATORY FAILURE; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; UNITED STATES; VOMITING;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-BACTERIAL AGENTS; DATA MINING; DRUG LABELING; HUMANS; MINOCYCLINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84861894709     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.967     Document Type: Article

References (25)

1. Frampton JE, Curran MP. Tigecycline. Drugs, 65, 2623-2635, discussion, 2636-2637 (2005).
2. McKeage K, Keating GM. Tigecycline: in community-acquired pneumonia. Drugs, 68, 2633-2644 (2008).
3. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, Woodford N. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the U.K.: a molecular, biological, and epidemiological study. Lancet Infect. Dis., 10, 597-602 (2010).
4. Michalopoulos A, Falagas ME. Treatment of Acinetobacter infections. Expert Opin. Pharmacother., 11, 779-788 (2010).
5. Giamarellou H. Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Int. J. Antimicrob. Agents, 36 (Suppl. 2), S50-S54 (2010).
6. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis., 48, 1-12 (2009).
7. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem- resistant) Acinetobacter infections: a review of the scientific evidence. J. Antimicrob. Chemother., 62, 45-55 (2008).
8. Giamarellou H, Poulakou G. Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs, 69, 1879-1901 (2009).
9. Falagas ME, Karageorgopoulos DE, Dimopoulos G. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Curr. Drug Metab., 10, 13-21 (2009).
10. Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J. Antimicrob. Chemother., 63, 775-780 (2009).
11. Pfizer Incorporated. "Tygacil (tigecycline) Full Prescribing Information": 〈http://www.pfizerpro.com/hcp/tygacil/prescribing〉, referenced 6 May, 2011.
12. Doan TL, Fung HB, Mehta D, Riska PF. Tigecycline: a glycylcycline antimicrobial agent. Clin. Ther., 28, 1079-1106 (2006).
13. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf., 10, 483-486 (2001).
14. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol. Drug Saf., 11, 3-10 (2002).
15. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM. A Bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol., 54, 315-321 (1998).
16. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the U.S. FDA's spontaneous reports database. Drug Saf., 25, 381-392 (2002).
17. Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol. Drug Saf., 18, 427-436 (2009).
18. Gould AL. Practical pharmacovigilance analysis strategies. Pharmacoepidemiol. Drug Saf., 12, 559-574 (2003).
19. Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJ, Yuen N. Novel statistical tools for monitoring the safety of marketed drugs. Clin. Pharmacol. Ther., 82, 157-166 (2007).
20. U.S. Food and Drug Administration. (FDA). "Adverse Event Reporting System (AERS)." 〈http://www.fda.gov/cder/aers〉, referenced November 19, 2011.
21. Sakaeda T, Kadoyama K, Okuno Y. Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations. Int. J. Med. Sci., 8, 487-491 (2011).
22. Sakaeda T, Kadoyama K, Yabuuchi H, Niijima S, Seki K, Shiraishi Y, Okuno Y. Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS. Int. J. Med. Sci., 8, 332-338 (2011).
23. Kadoyama K, Kuwahara A, Yamamori M, Brown JB, Sakaeda T, Okuno Y. Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS. J. Exp. Clin. Cancer Res., 30, 93 (2011).
24. Sakaeda T, Kadoyama K, Okuno Y. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system. PLoS ONE, 6, e28124 (2011).
25. Kadoyama K, Miki I, Tamura T, Brown JB, Sakaeda T, Okuno Y. Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations. Int. J. Med. Sci., 9, 33-39 (2012).